Edwards Lifesciences Corp (EW): 10-Q filed August 6, 2025

• Major Portfolio Restructuring: Completed divestiture of Critical Care business (~$1.2B revenue) to Becton Dickinson in September 2024, fundamentally reshaping company scale and operational focus while introducing separation-related contingent liabilities through Q2 2025

• Dual Financial Reality: Company now reports under discontinued operations framework, creating complexity in financial analysis with ongoing separation costs that will persist through mid-2025 and complicate year-over-year comparisons

• Increased Financial Volatility: Expanded derivative financial instrument positions across the balance sheet introduce mark-to-market accounting exposure that creates earnings volatility independent of operational performance

• Management Tone Reflects Transition: Neutral-to-cautious sentiment suggests management recognizes transformation benefits while acknowledging near-term execution risks and financial statement ambiguity during the separation period

• Investor Consideration: Until separation activities conclude, traditional financial metrics will be difficult to assess; investors should focus on continuing operations performance separately and monitor contingent liability developments